featured
Impact of Albiglutide on Glycemic Control and Reducing Prandial Insulin Use in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes Care
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
Diabetes Care 2020 Jul 21;[EPub Ahead of Print], J Rosenstock, A Nino, J Soffer, L Erskine, A Acusta, J Dole, MC Carr, J Mallory, P HomeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.